Insider Transactions in Q1 2023 at Nurix Therapeutics, Inc. (NRIX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 30
2023
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,412
-5.78%
|
$15,532
$11.78 P/Share
|
|
Jan 30
2023
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,207
+11.61%
|
-
|
|
Jan 30
2023
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
848
-10.46%
|
$9,328
$11.78 P/Share
|
|
Jan 30
2023
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,924
+19.18%
|
-
|
|
Jan 30
2023
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
924
-1.19%
|
$10,164
$11.78 P/Share
|
|
Jan 30
2023
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,886
+3.58%
|
-
|
|
Jan 30
2023
|
Stefani Wolff EVP and COO |
SELL
Open market or private sale
|
Direct |
424
-9.72%
|
$4,664
$11.78 P/Share
|
|
Jan 30
2023
|
Stefani Wolff EVP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
962
+18.06%
|
-
|